5MJC BCU 17: Updated Survival Analysis of the EGF104900 Randomized Study of Lapatinib Alone or Combined with Trastuzumab for HER2-Positive Breast Cancer Progressing on TrastuzumabUpdated Survival Analysis of the EGF104900 Randomized Study of Lapatinib Alone or Combined with Trastuzumab for HER2-Positive Breast Cancer Progressing on Trastuzumab Slides from a presentation at SABCS 2009 and transcribed comments from a recent interview with Mark D Pegram, MD (12/23/09)Dr Pegram is Full Professor of Medicine and Director for the Translational Research Program at the Braman Family Breast Cancer Research Institute at UM Sylvester Comprehensive Cancer Center in Miami, Florida. Presentation discussed in this issue: Go to previous Journal Club Go to next Journal Club
|